150 related articles for article (PubMed ID: 15987923)
1. Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Ryan DP; Fernandez-del Castillo C; Willett CG; Brugge WR; Sahani D; Brachtel EF
N Engl J Med; 2005 Jun; 352(26):2734-41. PubMed ID: 15987923
[No Abstract] [Full Text] [Related]
2. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
[No Abstract] [Full Text] [Related]
3. Management of borderline resectable pancreatic cancer.
Lal A; Christians K; Evans DB
Surg Oncol Clin N Am; 2010 Apr; 19(2):359-70. PubMed ID: 20159519
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Bednar F; Zenati MS; Steve J; Winters S; Ocuin LM; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2017 May; 24(5):1406-1413. PubMed ID: 27896518
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Cascinu S; Graziano F; Catalano G
Ann Oncol; 1999 Jan; 10(1):105-9. PubMed ID: 10076729
[TBL] [Abstract][Full Text] [Related]
7. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
Fogelman DR; Chen J; Chabot JA; Allendorf JD; Schrope BA; Ennis RD; Schreibman SM; Fine RL
Surg Oncol Clin N Am; 2004 Oct; 13(4):711-35, x. PubMed ID: 15350944
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
[TBL] [Abstract][Full Text] [Related]
9. [A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Moriyama M; Sawada S; Matsui K; Yoshioka I; Shibuya K; Osawa S; Yoshida T; Nagata T; Tsukada K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2187-9. PubMed ID: 25731465
[TBL] [Abstract][Full Text] [Related]
10. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: progress made.
Simianu VV; Zyromski NJ; Nakeeb A; Lillemoe KD
Acta Oncol; 2010 May; 49(4):407-17. PubMed ID: 20059311
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
14. Management of locally advanced adenocarcinoma of the pancreas.
Ryan DP; Willett CG
Hematol Oncol Clin North Am; 2002 Feb; 16(1):95-103. PubMed ID: 12063831
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
16. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
17. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
[TBL] [Abstract][Full Text] [Related]
18. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
André T; Balosso J
J Chir (Paris); 1999 Dec; 136(6):309-17. PubMed ID: 10675820
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
